Trading involves risk
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Trading involves risk
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
English (International)
ACADIA Pharmaceuticals Inc
Closed
SectorHealthcare
20.95 -2.42
Overview
Share price change
24h
Min
20.81
Max
21.4
Income | -125M 19M |
|---|---|
Sales | -15M 244M |
P/E Sector Avg | 16.097 40.527 |
Profit margin | 7.771 |
Employees | 653 |
EBITDA | 7.1M 19M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +35.69% upside |
Next Earnings | 5 Aug 2025 |
|---|
Market Cap | 412M 3.7B |
|---|---|
Previous open | 23.37 |
Previous close | 20.95 |
News Sentiment
By Acuity
50%
50%
163 / 380 Healthcare
Technical Score
By Trading Central
Confidence
Bullish Evidence
ACADIA Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
ACADIA Pharmaceuticals Inc Forecast
Price Target
By TipRanks
35.69% upside
12 Months Forecast
Average 28.82 USD 35.69%
High 38 USD
Low 15 USD
Based on 19 Wall Street analysts offering 12 month price targets forACADIA Pharmaceuticals Inc - Dist in the last 3 months.
Sentiment
By Acuity
163 / 380 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
